Ansaripour, A., Uyl-de Groot, C.A. de, Foroozanfar, M., Rahimimoghadam, S. & Redekop, W.K. (2016). Which is more important for doctors in a middle-income country, a national guideline or the medical literature? An adherence survey of trastuzumab use for breast cancer in Iran. Journal of Cancer Policy, 9, 8-13. doi:

Attema, A.E., Brouwer, W.B.F., l’Haridon, O. & Pinto-Prades, J.L. (2016). An elicitation of utility for quality of life under prospect theory. Journal of Health Economics, 48, 121-134. doi:

Baal, P.H.M. van, Peters, F., Mackenbach, J.P. & Nusselder, W.J. (2016). Forecasting differences in life expectancy by education. Population Studies. A Journal of Demography, 70 (2), 201-216. doi: 10.1080/00324728.2016.1159718

Baal, P.H.M. van, Hoogendoorn, M. & Fischer, A. (2016). Preventing dementia by promoting physical activity and the long-term impact on health and social care expenditures. Preventive Medicine, 85 (4), 78-83. doi: 10.1016/j.ypmed.2016.01.013

Bakx, P.L.H., Doorslaer, E.K.A. van & O’Donnell, O.A. (2016). Spending on Health Care in the Netherlands: Not Going so Dutch. Fiscal Studies (London), 37 (3-4), 593-625. doi:

Bindels, J., Ramaekers, B, Corro Ramos, I., Mohseninejad, L., Knies, S., Grutters, J, Postma, M., Al, M.J., Feenstra, TL & Joore, M. (2016). Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. Pharmacoeconomics (Print), 34 (3), 315-322. doi:

Blommestein, H.M., Verelst, S.G.R., Groot, S. de, Huijgens, P.C., Sonneveld, P. & Uyl-de Groot, C.A. de (2015). A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. European Journal of Haematology, 96 (2), 198-208. doi:

Blommestein, H.M., Groot, S. de, Aarts, MJ, Vemer, P., de Vries, R., Abeelen, A.F.M., Posthuma, E.F.M. & Uyl-de Groot, C.A. de (2016). Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. Leukemia Research, 50, 37-45. doi: 10.1016/j.leukres.2016.09.005

Blommestein, H.M., Armstrong, N, Ryder, S, Deshpande, S, Worthy, G, Noake, C., Riemsma, R, Kleijnen, J., Severens, J.L. & Al, M.J. (2016). Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. Pharmacoeconomics (Online), 34 (1), 23-31. doi:

Boland, M.R.S., Kruis, A.L., Tsiachristas, A., Assendelft, W.J.J., Gussekloo, J, Blom, CMG, Chavannes, NH & Rutten – van Molken, M.P.M.H. (2015). Cost-effectiveness of integrated COPD care: the RECODE cluster randomised trial. BMJ Open Gastroenterology, 5, 1-10. doi:

Boland, M.R.S., Kruis, A.L., Huygens, S.A., Tsiachristas, A., Assendelft, W.J.J., Gussekloo, J, Blom, CMG, Chavannes, NH & Rutten – van Molken, M.P.M.H. (2015). Exploring the variation in implementation of a COPD disease management programma and its impact on health outcomes: a post hoc analysis of the RECODE cluster randomised trial. npj Primary Care Respiratory Medicine, 25 (15071), 1-9. doi:

Boland, M.R.S., van Boven, J.F., Kruis, A.L., Chavannes, NH, Van der Molen, T., Goossens, L.M.A. & Rutten – van Molken, M.P.M.H. (2016). Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence. Respiratory Medicine, 110, 34-45. doi:

Bond, C.M., Bruhn, H, Bont, A.A. de, Exel, N.J.A. van, Busse, R., Sutton, M. & Elliot, R.F. (2016). The iMpact on practice, oUtcomes and costs of New roles for health pROfeSsionals: a study protocol for MUNROS. BMJ Open Gastroenterology, 6, e010511. doi:

Bonfrer, I.E.J. & Gustafsson-Wright, E. (2016). Health shocks, coping strategies and foregone healthcare among agricultural households in Kenya. Global Public Health: An International Journal for Research, Policy and Practice, 19, 1-22. doi: 10.1080/17441692.2015.1130847

Bonfrer, I.E.J., Breebaart, L. & Poel, E. van de (2016). The Effects of Ghana’s National Health Insurance Scheme on Maternal and Infant Health Care Utilization. PLoS One (print), 11 (e01655623). doi: 10.1371/journal.pone.0165623

Bont, A.A. de, Exel, N.J.A. van, Coretti, S., Guldem Okem, Z., Janssen, M., Lofthus Hope, K., Ludwicki, T., Zvonickova, M., Zander, B., Bond, C.M. & Wallenburg, I. (2016). Reconfiguring health workforce: A case-based comparative study explaining the increasingly diverse professional roles in Europe. Bmc Health Services Research, 16 (1), 637-651. doi: 10.1186/s12913-016-1898-0

Bovenkamp, H.M. van de & Dwarswaard, J. (2016). Dilemma Rust geven of activeren? Nursing.

Bredenkamp, C. & Buisman, L.R. (2016). Financial protection from health spending in the Philippines: policies and progress. Health Policy and Planning, 31 (7), 919-927. doi:

Breukelen – van der Stoep, D.F., Zeben, D van, Klop, B, Geijn, GJM van de, Janssen, HJW, Meulen, N van der, Vries, MA de, Hazes, M., Birnie, E. & Cabezas, MC (2016). Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis. Rheumatology, 55 (7), 1210-1216. doi:

Buisman, L.R., Luime, J.J., Oppe, M., Hazes, J.M.W. & Rutten – van Molken, M.P.M.H. (2016). A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis. Arthritis Research & Therapy, 18 (1):135. doi:

Buisman, L.R., Rutten – van Molken, M.P.M.H., Postmus, D., Luime, J.J., Uyl-de Groot, C.A. de & Redekop, W.K. (2016). The early bird catches the worm: early cost-effectiveness analysis of new medical tests. International Journal of Technology Assessment in Health Care, 32 (1-2), 46-53. doi:

Buisman, L.R. (2016, Juni 30). Early cost-effectiveness of medical tests in rheumatoid arthritis and ischemic stroke. EUR. Prom./coprom.: prof.dr. M.P.M.H. Rutten – van Molken & dr. W.K. Redekop.

Burgers, L.T., Redekop, W.K., Al, M.J., Lhachimi, S.K., Armstrong, N, Walker, S., Rothery, C., Westwood, M. & Severens, J.L. (2016). Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. European Journal of Health Economics (HEPAC), 1-12. doi:

Burgers, L.T., Vahl, AC, Severens, J.L., Wiersema, AM, Cuypers, P.W.M., Verhagen, H.J.M. & Redekop, W.K. (2016). Cost-effectiveness of Elective Endovascular Aneurysm Repair Versus Open Surgical Repair of Abdominal Aortic Aneurysms. European Journal of Vascular and Endovascular Surgery, 52 (1), 29-40. doi: 10.1016/j.ejvs.2016.03.001

Burgers, P.T.P.W., Hoogendoorn, M., Woensel, EAC Van, Poolman, RW, Bhandari, M, Patka, P. & Lieshout, E.M.M. van (2016). Total medical costs of treating femoral neck fracture patients with hemi- or total hip arthroplasty: a cost analysis of a multicenter prospective study. Osteoporosis International, 27 (6), 1999-2008. doi: 10.1007/s00198-016-3484-z

Corro Ramos, I., Lhachimi, SK, Gerber-Grote, A. & Al, M.J. (2016). Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework. Medical Decision Making. doi: 10.1177/0272989X16636856

Exuzides, A., Colby, C.E., Briggs, A, Lomas, DA, Rutten – van Molken, M.P.M.H., Tabberer, M., Chambers, M., Muellerova, H., Locantore, N., Risebrough, N.A., Ismaila, A.S. & Gonzalez-McQuire, S. (2015). Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Datra from the ECLIPSE Study. Medical Decision Making. doi:

Fugel, H.J., Nuijten, M., Postma, M. & Redekop, W.K. (2016). Economic evaluation in stratified medicine: methodological issues and challenges. Frontiers in pharmacology, 7:113. doi: 10.3389/fphar.2016.00113

Fugel, H.J. (2016, Juni 17). Economics of Stratified Medicine. Rijksuniversiteit Groningen. Prom./coprom.: M. Postma, dr. M.J. Nuijten & dr. W.K. Redekop.

Gheorghe, M., Wubulihasimu, P., Peters, F., Nusselder, W.J. & Baal, P.H.M. van (2016). Health inequalities in the Netherlands: trends in quality-adjusted life expectancy (QALE) by educational level. European Journal of Public Health, 26 (5), 794-799. doi: 10.1093/eurpub/ckw043

Gheorghe, M., Picavet, S, Verschuren, M., Brouwer, W.B.F. & Baal, P.H.M. van (2016). Health losses at the end of life: a Bayesian mixed beta regression approach. Journal of the Royal Statistical Society. Series A. Statistics in Society. doi: 10.1111/rssa.12230

Gheorghe, M. (2016, September 15). Quantitative Approaches in Monitoring Population Quality Of Life. EUR. Prom./coprom.: prof.dr. W.B.F. Brouwer & dr. P.H.M. van Baal.

Goossens, L.M.A., Overbeek, J, Driessen, M. & Rutten – van Molken, M.P.M.H. (2016). Effect van therapietrouw op exacerbaties is moeilijk te schatten met beschikbare real life data voor astma en COPD. Pharmaceutisch Weekblad, 1, a1632.

Groot, S. de, Linden, N. van der, Franken, M.G., Blommestein, H.M., Leeneman, B., Rooijen, E.M. van, Hoeven, J.J.M. van der, Wouters, MW, Westgeest, H.M. & Uyl-de Groot, C.A. de (2016). Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value in Health. doi: 10.1016/j.jval.2016.02.007

Groot, S. de, Redekop, W.K., Sleijfer, S., Oosterwijk, E., Bex, A., Kiemeney, L.A.L.M. & Uyl-de Groot, C.A. de (2016). Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry. Urology, 95, 121-127. doi:

Groot, S. de, Sleijfer, S., Redekop, W.K., Oosterwijk, E., Haanen, JB, Kiemeney, L.A.L.M. & Uyl-de Groot, C.A. de (2016). Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. Bmc Cancer, 16, 364. doi:

Groot, S. de. Evidence from clinical practice to support healthcare decision making, evaluation of clinical and economic outcomes of new therapies for metastatic renal cell carcinoma. EUR. Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, L.A.L.M. Kiemeney & dr. W.K. Redekop.

Hanly, P, Koopmanschap, M.A. & Sharp, L (2016). Valuing productivity costs in a changing macroeconomic environment: the estimation of colorectal cancer productivity costs using the friction cost approach. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-015-0698-5

Hoogendoorn, M., Feenstra, T.L., Asukai, Y, Briggs, AH, Borg, S. ter, Dal Negro, RW, Hansen, RN, Jansson, SA, Leidl, R., Risebrough, N, Samyshkin, Y, Wacker, ME & Rutten – van Molken, M.P.M.H. (2016). Patient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine? Value in Health, 19 (6), 800-10. doi: 10.1016/j.jval.2016.04.002

Hoogenveen, R.T., Boshuizen, H.C., Engelfriet, PM & Baal, P.H.M. van (2016). You Only Die Once: Accounting for Multi-Attributable Mortality Risks in Multi-Disease Models for Health-Economic Analyses. Medical Decision Making. doi: 10.1177/0272989X16658661

Horn, E.K., Verheul, R., Thunnissen, M, Delimon, J, Goorden, M., Roijen, L. van, Soons, M, Meerman, AMMA, Ziegler, UM, Rossum, BV, Stijnen, T, Emmelkamp, P.M.G. & Busschbach, J.J.V. van (2016). COST-EFFECTIVENESS OF SHORT-TERM INPATIENT PSYCHOTHERAPY BASED ON TRANSACTIONAL ANALYSIS IN PATIENTS WITH PERSONALITY DISORDER. Journal of Personality Disorders, 30 (4), 483-501. doi: 10.1521/pedi_2015_29_210

Kanters, T.A. (2016, December 08). Health Technology Assessment Of Orphan Drugs : The example of Pompe disease. EUR. Prom./coprom.: prof.dr. M.P.M.H. Rutten – van Molken, Prof. Dr. A.T. van der Ploeg & dr. L. Hakkaart-van Roijen.

Karlsdotter, K, Bushe, C, Hakkaart-van Roijen, L., Sobanski, E, Kan, C.C., Lebrec, J, Kraemer, S.A. & Dieteren, N.A.H.M. (2016). Burden of illness and health care resource utilization in adult psychiatric outpatients with attention-deficit/hyperactivity disorder in Europe. Current Medical Research & Opinion, 32 (9), 1547-1556. doi:

Lenk, E.J., Redekop, W.K., Luyendijk, M., Rijnsburger, A.J. & Severens, J.L. (2016). Productivity Loss Related to Neglected Tropical Diseases Eligible for Preventive Chemotherapy: A Systematic Literature Review. PLoS Neglected Tropical Diseases (print), 10 (2), 1-19. doi:

Linden, N. van der, Bongers, M.L., Coupe, VMH, Smit, E.F., Groen, H.J.M., Welling, A., Schramel, FMNH & Uyl-de Groot, C.A. de (2016). Costs of non-small cell lung cancer in the Netherlands. Lung Cancer, 91, 79-88. doi:

Linden, N. van der, Flach, G.B, Bree, R. de & Uyl-de Groot, C.A. de (2016). Cost–utility of sentinel lymph node biopsy in cT1–T2N0 oral cancer. Oral Oncology, 53, 20-26. doi:

Lötters, F.J.B., van den Bergh, J.P, Vries, F. de & Rutten – van Molken, M.P.M.H. (2016). Current and Future Incidence and Costs of Osteoporosis-Related Fractures in the Netherlands: Combining Claims Data with BMD Measurements. Calcified Tissue International, 98, 235-243. doi:

Mason, H., Exel, N.J.A. van, Baker, R., Brouwer, W.B.F. & Donaldson, C. (2016). From representing views to representativeness of views: Illustrating a new (Q2S) approach in the context of health care priority setting in nine European countries. Social Science & Medicine, 166, 205-213. doi: 10.1016/j.socscimed.2016.08.036

McLean, S, Hoogendoorn, M., Hoogenveen, R.T., Feenstra, T.L., Wild, S, Simpson, CR, Rutten – van Molken, M.P.M.H. & Sheikh, A (2016). Projecting the COPD population and costs in England and Scotland: 2011 to 2030. Scientific Reports, 6, 31893. doi: 10.1038/srep31893

Morton, A, Adler, A.L., Bell, D, Briggs, A, Brouwer, W.B.F., Claxton, K., Craig, N., Fischer, A., McGregor, P & Baal, P.H.M. van (2016). Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. Health Economics, 25 (8), 933-938. doi: 10.1002/hec.3366

Nooten, F.E. van, Exel, N.J.A. van, Eriksson, D. & Brouwer, W.B.F. (2016). “Back to the future”: Influence of beliefs regarding the future on TTO answers. Health and Quality of Life Outcomes, 14, 4. doi:


Oemrawsingh, R.M., Akkerhuis, K.M., Vark, L.C. van, Redekop, W.K., Rudez, G., Remme, W.J., Bertrand, M.E., Fox, K.M., Ferrari, R., Danser, A., Maat, M.P.M. de, Simoons, M.L., Brugts, J.J. & Boersma, E. (2016). Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. Journal of the American Heart Association, 5 (3), e002688. doi:

Phillips, KA, Payne, K. & Redekop, W.K. (2016). Personalized Medicine: Economic Evaluation and Evidence. In R.M. Scheffler (Ed.), World Scientific Handbook of Global Health Economics and Public Policy: Volume 2: Health Determinants and Outcomes (pp. 123-150). World Scientific.

Posthumus, A.G., Birnie, E., Veen, M.J. van, Steegers, E.A.P. & Bonsel, G.J. (2016). An antenatal prediction model for adverse birth outcomes in an urban population: The contribution of medical and non-medical risks. Midwifery, 38, 78-86. doi:

Rappange, D.R., Brouwer, W.B.F. & Exel, N.J.A. van (2016). Rational expectations? An explorative study of subjective survival probabilities and lifestyle across Europe. Health Expectations, 19 (1), 121-137. doi: 10.1111/hex.12335

Rappange, D.R. (2016, Mei 19). Future Health: A Policy and Individual Perspective. EUR. Prom./coprom.: prof.dr. W.B.F. Brouwer & prof.dr. N.J.A. van Exel.

Raza, W.A., Poel, E. van de, Panda, P., Dror, D. & Bedi, A.S. (2016). Healthcare seeking behavior among self-help group households in rural Bihar and Uttar Pradesh. Bmc Health Services Research, 16 (1), 1-13. doi:

Richters, A, Melis, RJF, Exel, N.J.A. van, Olde Rikkert, M.G.M. & Marck, M.A. van der (2016). Perseverance time of informal caregivers for institutionalized elderly: construct validity and test-retest reliability of a single-question instrument. Journal of the American medical directors association, 17 (8), 761-762. doi: 10.1016/j.jamda.2016.05.001

Riemsma, R, Corro Ramos, I., Birnie, R., Buyukkaramikli, N.C., Armstrong, N, Ryder, S, Duffy, S, Worthy, G, Al, M.J., Severens, J.L. & Kleijnen, J. (2016). Integrated sensor-augmented pump therapy system [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. Health Technology Assessment, 20 (17). doi:

Rosendaal, N.T., Hendriks, M.E., Verhagen, M.D., Bolarinwa, O.A., Sanya, E.O., Kolo, P.M., Adenusi, P., Agbede, K., Eck, D. van, Tan, S.S., Akande, T.M., Redekop, W.K., Schultsz, C & Gomez, G.B. (2016). Costs and Cost-Effectiveness of Hypertension Screening and Treatment in Adults with Hypertension in Rural Nigeria in the Context of a Health Insurance Program. PLoS One (print), 11 (6), e0157925. doi:

Scheerhagen, M., Stele, HF van, Tholhuijsen, DJC, Birnie, E., Franx, A & Bonsel, G.J. (2016). Applicability of the ReproQ client experiences questionnaire for quality improvement in maternity care. PEERJ, 4. doi: 10.7717/peerj.20922

Selya-Hammer, C, Guix, N.G.R, Baldwin, M, Ternouth, A, Miravitlles, M., Rutten – van Molken, M.P.M.H., Goossens, L.M.A., Buyukkaramikli, N.C. & Acciai, V (2016). Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Therapeutic Advances in Respiratory Disease, 10 (5), 391-401. doi:

Slok, A.H.M., Bemelmans, T.C.H., Kotz, D., Van der Molen, T., Kerstjens, H.A.M., Veen, JCCM in’t, Chavannes, NH, Asijee, G.M., Rutten – van Molken, M.P.M.H. & van Schayk, O.C.P. (2016). The Assessment of Burden of COPD (ABC) Scale: A Reliable and Valid Questionnaire. COPD-Journal of chronic obstructive pulmonary disease, 13 (4), 431-438. doi:

Tan, S.S., Teirlinck, CH, Dekker, J, Goossens, L.M.A., Bohnen, A.M., Verhaar, J.A.N., Es, P.P. van, Koes, B.W., Bierma-Zeinstra, S., Luijsterburg, P.A.J. & Koopmanschap, M.A. (2016). Cost-utility of exercise therapy in patients with hip osteoarthritis in primary care. Osteoarthritis and Cartilage, 24 (4), 581-588. doi: 10.1016/j.joca.2015.11.010

Tan, S.S., Slot, W.M.A. van der, Ketelaar, M, Becher, J.G., Dallmeijer, AJ, Smits, D.W. & Roebroeck, M.E. (2016). Factors contributing to the longitudinal development of social participation in individuals with cerebral palsy. Research in Developmental Disabilities, 57, 125-135. doi: 10.1016/j.ridd.2016.03.015

Teirlinck, CH, Luijsterburg, P.A.J., Dekker, J, Bohnen, A.M., Verhaar, J.A.N., Koopmanschap, M.A., Es, P.P. van, Koes, B.W. & Bierma-Zeinstra, S.M.A. (2016). Effectiveness of exercise therapy added to general practitioner care in patients with hip osteoarthritis: a pragmatic randomized controlled trial. Osteoarthritis and Cartilage, 24 (1), 82-90. doi:


Thielen, W.F., Mastrigt, GAPG van, Burgers, L.T., Bramer, W.M., Majoie, H.J.M., Evers, S.M.A.A. & Kleijnen, J. (2016). How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3). Expert review of pharmacoeconomics & outcomes research, 16 (6), 1-17. doi: 10.1080/14737167.2016.1246962

Thielen, W.F., Blommestein, H.M. & Uyl-de Groot, C.A. de (2016). Using appropriate methods in cost-effectiveness analyses: the case of allogeneic hematopoietic cell transplantation in sickle cell disease. Biology of Blood and Marrow Transplantation, 22 (11), 2109-2110. doi: 10.1016/j.bbmt.2016.08.022

Thielen, W.F. (2016). Entering your heart: how barely tested medical innovations find their way into clinical practice. In M.T. Brancaccio (Ed.), Governance of Health Care Innovation. Excursions into Politics, Science and Citizenship (pp. 19-40). Maastricht: Creative Commons License CC BY-NC.

Tsiachristas, A., Burgers, L.T. & Rutten – van Molken, M.P.M.H. (2015). Cost-Effectiveness of Disease Management Programs for Cardiovascular Risk and COPD in The Netherlands. Value in Health, 18 (8), 977-986. doi:

Vemer, P., Corro Ramos, I., Voorn, G.A.K. van, Al, M.J. & Feenstra, TL (2016). AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users. Pharmacoeconomics (Print), 34 (4), 349-361. doi: 10.1007/s40273-015-0327-2

Verhoef, T.I., Redekop, W.K., Langenskiold, S., Kamali, F., Wadelius, M., Burnside, G., Maitland-van der Zee, A.H., Hughes, D.A. & Pirmohamed, M. (2016). Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics Journal, 16 (5), 478-484. doi: 10.1038/tpj.2016.41

Versteegh, M.M., Vermeulen, KM, Evers, S.M.A.A., de WIt, G.A., Prenger, R & Stolk, E.A. (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health, 19 (4), 343-352. doi: 10.1016/j.jval.2016.01.003

Versteegh, M.M., Knies, S. & Brouwer, W.B.F. (2016). From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare. Pharmacoeconomics (Print), 34 (11), 1071-1074. doi:

Versteegh, M.M. (2016). Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (Online), 34, 1133-1144. doi: 10.1007/s40273-016-0421-0

Versteegh, M.M. & Brouwer, W.B.F. (2016). Patient and general public preferences for health states: A call to reconsider current guidelines. Social Science & Medicine, 165, 66-74. doi:

Versteegh, M.M. (2016). Doelmatige gezondheidszorg: hoe besteden we onze euro’s het beste? In M M Levi (Ed.), De dokter en het geld. Diagnosis uitgevers.